EMERGENT BIOSOLUTIONS INC. Restricted Cash
EMERGENT BIOSOLUTIONS INC. (EBS) had Restricted Cash of $1.20 million as of 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Balance Sheet › Assets › Restricted Cash and Investments
us-gaap:RestrictedCash · last filed 2026-08-06
- 2026-06-30: Restricted Cash $1.20M.
- 2026-03-31: Restricted Cash $1.20M.
- 2025-12-31: Restricted Cash $3.70M.
- 2025-09-30: Restricted Cash $3.70M.
| Period end | Restricted Cash |
|---|---|
| 2026-06-30 | $1.20M 10-Q · filed 2026-08-06 |
| 2026-03-31 | $1.20M 10-Q · filed 2026-05-01 |
| 2025-12-31 | $3.70M 10-K · filed 2026-02-27 |
| 2025-09-30 | $3.70M 10-Q · filed 2025-10-30 |
| 2025-06-30 | $3.70M 10-Q · filed 2026-08-06 |
| 2025-03-31 | $3.70M 10-Q · filed 2026-05-01 |
| 2024-12-31 | $6.10M 10-K · filed 2026-02-27 |
| 2024-09-30 | $6.50M 10-Q · filed 2025-10-30 |
| 2024-06-30 | $1.30M 10-Q · filed 2025-08-07 |
| 2024-03-31 | $500.00K 10-Q · filed 2025-05-08 |
| 2023-12-31 | $0.00 10-K · filed 2026-02-27 |
| 2023-09-30 | $0.00 10-Q · filed 2024-11-07 |
| 2023-06-30 | $0.00 10-Q · filed 2024-08-07 |
| 2023-03-31 | $0.00 10-Q · filed 2024-05-02 |
| 2022-12-31 | $0.00 10-K · filed 2025-03-04 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ENANTA PHARMACEUTICALS INC (ENTA) | United States | $0.349B | -6.72 |
| Larimar Therapeutics, Inc. (LRMR) | United States | $0.344B | -1.83 |
| Vogenx, Inc. (VOGX) | United States | $0.355B | |
| Benitec Biopharma Inc. (BNTC) | United States | $0.337B | -10.08 |
| BioAge Labs, Inc. (BIOA) | United States | $0.333B | -11.88 |
| BridgeBio Oncology Therapeutics, Inc. (BBOT) | United States | $0.320B | -3.35 |
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| Rezolute, Inc. (RZLT) | United States | $0.382B | -6.45 |